Distinct linker sequences were introduced into the protease-sensitive V, domain of protein kinase C-a and the mutant proteins were expressed in COS-1 cells. Partially purified preparations of these mutants were functionally similar to wild-type protein kinase C-a, however their susceptibility to m-calpain was quite distinct, with one mutant being insensitive to cleavage. The three mutants, after expression in COS-1 cells, were found to behave in a manner indistinguishable from wild-type protein kinase C-a with respect to subcellular distribution, acute responses to 12Otetradecanoyl-phorbol 13-acetate and 3 2-0-tetradecanoyl-phorbol-13-acetate-induced down-regulation. The data imply that down-regulation of protein kinase C-a is likely to involve a general degradative process rather than cleavage by a site-specific protease.
The protein-kinase-C (PKC) gene family is comprised of at least nine genes [l-31. Most, but not all of these protein kinases share a dependence upon diacylglycerol and phospholipid for activity. Activated PKC is thus membranekesicle associated both in vitro and in vivo. Chronic activation of PKC in vivo through the action of phorbol esters frequently leads to a decrease in steady-state expression levels. This phenomenon, down-regulation, is due to an increased rate of proteolysis [4-61, which can occur in the absence of any change in the rate of synthesis. Thus in vivo data are consistent with the notion that PKC in its active state is in a more open conformation and is thus accessible to proteases. Empirical evidence for an open conformation and exposure of a proteolytically sensitive domain has come both from studies on sensitivity to the calcium-activated neutral proteases (m-calpain and p-calpain) and their sites of action [7] , and through studying the binding of a monoclonal antibody [8] . These data demonstrate that the variable region, V3, between the conserved regulatory domain and the catalytic domain ( Fig. l) , is the site of protease cleavage and that this V, region is more accessible in PKC following binding of its activators. The altered exposure of the V, region on activation provides one explanation for the down-regulation elicited in vivo by chronic exposure to phorbol esters. Such a passive effect of phorbol esters in inducing down-regulation is consistent with the observation that kinase-deficient PKC mutants can also be down-regulated [9, lo] ). However, these kinase-deficient mutants have not been expressed in PKC-deficient conditions. Thus, while a kinase-negative PKC-a can be down-regulated when expressed in COS cells, these cells also retain an endogenous wild-type PKC-a that itself shows a typical down-regulation response and may be responsible for driving such a response for the mutant. As a first step in assessing the mechanism and role of proteolysis/down-regulation in PKC action, it would be desirable to define the protease(s) involved in this process. The investigations described in this study were designed to address this issue through mutagenesis of the proteolytically sensitive hinge domain of PKC-a. The results imply that calpain is not responsible for down-regulation. Furthermore, it is unlikely that any single, sequence-specific protease is involved.
MATERIALS AND METHODS

Materials
Chemicals and biochemicals were from Sigma or BDH unless indicated. [y-32P]ATP and ECL reagents were from Amersham International. Calpain (m-form) was purified as described previously [ 121.
Preparation and expression of PKC-a V, domain mutants
The V, domain of bovine PKC-a [13] between the SacI site (bp 953) and BstXI site (bp 1041) was replaced with one of three PCR fragments derived from predicted hinge regions of PKC-P, [14] , PLC-S, [15] or p85a [16] ; the constructions are summarised in Fig. 1 . The fragments were obtained from the respective cloned cDNAs by PCR employing sense and antisense oligonucleotides flanked by SacI and BstXI sites,
LGGLLPPGGEGGPEATVSDEDEAAEMEDES respectively. The products were cut at these restriction sites and cloned into the Bluescript plasmid (Pharmacia) and sequenced. The various mutant fragments were subcloned as Sac1 -BstXI fragments back into a wild-type PCK-a BamHI-SmaT fragment in Bluescript also restricted with Sac1 and BstXI. The full-length mutants were created by replacing the wild-type PCK-a BamHI -SmaI fragment with each of the mutant fragments. This procedure yielded the phospholipase-C-P,-derived mutant PCK-a V$,, the phospholipase-C-&,-derived mutant PCK-a V,& and the p85a-derived mutant PKC-a pSSV,. The full-length wild-type and mutant PKC-a species were subcloned into the PKS-1 expression vector [17] . Culture and transfection of COS-1 cells were as described previously [ 181.
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Extraction and fractionation or wild-type and mutant PKC
PKC-a and the V, mutants were extracted either directly into Laemmli sample buffer for analysis by SDSPAGE [19] , or were scraped into 20 mM Tris/HCI, pH 7.5, 5 mM EDTA, 5 mM EGTA, 0.3% (by vol.) 2-mercaptoethanol, 10 mM benzamidine, 50 pg/ml phenylmethylsulfonyl fluoride, 100 pg/ml leupeptin, homogenised in a Dounce and fractionated by centrifugation as described previously [20] . The fractionation yielded soluble (cytosolic), neutral detergent soluble (particulate), and detergent insoluble (cytoskeleton) fractions.
In experiments investigating calpain sensitivity and functional integrity of the proteins, the transfected cells were lysed directly in 20 mM Tris/HCI, pH 7.5, 5 mM EDTA, 5 mM EGTA, 0.3% (by vol.) 2-mercaptoethanol, 10 mM benzamidine, 50 pg/ml phenylmethylsulfonyl fluoride, 100 pg/ml leupeptin, 1% (by vol.) Triton X-100 and the extract was cleared by centrifugation in a microfuge for 10 min at 4°C. The supernatant was loaded onto a 1 ml heparinSepharose column (Pharmacia) attached to an FPLC instrument. The bound protein was eluted with a linear gradient of 0-1 .0 M NaCl in 20 mM Tris/HCl, 2 mM EDTA, 10 mM benzamidine, 0.3% 2-mercaptoethanol, 0.1 % (by vol.) Triton X-100. PKC activity was determined using the substrate histone 111-S as described previously [21] . PKC was detected with antisera to the C-terminus of PCK-a ~211 using the ECL system for detection.
RESULTS
Mutations in the V, domain of PCK-a were introduced as outlined in Fig. 1 . These mutations were designed on the premise that the mutant sequences were derived from proteins which, like PKC, are active at the membrane and them-
Proteolysis of wild-type and mutant PKC
PKC-a and V, mutants were isolated by chromatography on heparin -Sepharose as described above. The fractions with highest activity were employed to follow the susceptibility to calpain cleavage. The ions for calpain treatment were initially optimised on purified PKC-P, (data not shown) and were as follows: 80 yl sample contained 60 yl partially purified PKC-a or PKC-a V, mutant, 10 pl calpain (2 mg/ml diluted tenfold in 20 mM Tris/HCl, pH 7.5,O.l mg/ml bovine serum albumin, 1 mM dithiothreitol) or dilution buffer and 10 yl 40 mM Ca". Incubations were carried out at 30°C for the times indicated in the figure legends and reactions were stopped by addition of an equal volume of Laemmli sample buffer [19] to an aliquot of reaction mixture. Samples were boiled, the proteins were separated by SDS/PAGE [19] and selves are not known to be susceptible to proteolysis within these specific sequences. On transfection, all three V, domain mutants were found to be expressed in COS-1 cells, at a level comparable to that of the transfected wild-type PKC-a.
To assess directly the potential role of calpain in the process of down-regulation, wild-type and V,mutant forms of PCK-a were purified by heparin-Sepharose chromatography for proteolytic studies. All three V, mutant proteins behaved like wild-type PKC-a and showed typical phosphatidylserine 12-0-tetradecanoyl-phorbol 13-acetate (TPA)-dependent histone kinase activity (Fig. 2) . This provides further evidence that the V, region of PCK-a acts as a 'spacer', conferring no apparent functional property.
The partially purified PKC-a and V, mutants were subjected to proteolysis by m-calpain (Fig. 3) . This provided evidence for a hierarchy of sensitivity to m-calpain cleavage.
with the pXSV, mutant (Fig. 3, lanes 10-12) more susceptible than wild-type PKC-a (lanes 1-3) and the V,6, mutant much less sensitive than wild-type PKC-a, but still cleaved at a slow rate (Fig. 3, lanes 7-9) . The product of cleavage for this latter mutant had molecular mass 52 kDa compared to 47 kDa for the wild-type PKC-a and p85V, mutant. By contrast, the PKC-a V$, mutant was insensitive to proteolysis by m-calpain (lanes [4] [5] [6] .
After establishing the hierarchy of sensitivity to m-calpain cleavage, the wild-type PKC-rx and V, mutants were further investigated in COS cells to determine their susceptibility to TPA-induced down-regulation. Transfected COS cells were exposed to TPA (200 nM) for 24 h prior to fractionation and the PKC content was analysed. It is evident that none of the altered V, domains confer down-regulation insensitivity (Fig. 4) . The behaviour of the V, domain mutants was further investigated with respect to their subcellular localisation. Like the wild-type PCK-a, all mutants were found distributed between the cytosol, Triton X-100 soluble and Triton insoluble fractions ( Fig. 5 ; data not shown). Upon acute TPA stimulation, there was a partial shift from the cytosol to the Triton X-100 soluble fraction. After long-term TPA treatment, all forms were down-regulated and the remaining antigen was only observed on prolonged exposure of the X-ray film and was predominantly in the Triton X-100 insoluble compartment.
DISCUSSION
The mutations introduced in the V, domain of PCK-a were designed to assess sequence specificity in this domain for down-regulation and the role of calpain in TPA-induced PKC down-regulation. All three V, mutants were found to respond to acute TPA treatment in vivo and were activated by TPA (in the presence of phosphatidylserine) in vitro. Similarly, all three mutants were found to down-regulate in response to TPA. This contrasts with the susceptibility to cleavage by m-calpain where there was a clear hierarchy: p85V, > wild-type > V,6, with respect to the rate of cleavage in vitro ; V,pz was apparently insensitive to m-calpain cleavage. (The susceptibility of the PKC-a p8SV, mutant to m-calpain cleavage suggests that this p85a sequence may confer susceptibiity in the intact phosphatidylinositol 3-kinase context; this has yet to be determined). The implication in this instance is that m-calpain is not responsible for TPA-induced PKC-a down-regulation in vivo, but it remains possible that p-calpain may play a role.
The nature of the mutations made in this study and their lack of impact on down-regulation, suggest that no single protease with sequence specificity is likely to be involved in this process. This would imply that a more general process or multiple proteases may be involved in PKC down-regulation. One such route of proteolysis might be afforded by proteasome-mediated degradation [ 221 ; alternatively, delivery of PKC to lysosomes may be involved. This latter possibility would be consistent with a role for PKC in the activation of vesicle trafficking (Goode, N., Hajibagheri, N., Warren, G. and Parier, P. J.. unpublished results). Since TPA-bound (activated) PKC would be membrane associated, it is likely to be processed through vesicle-sorting pathways and in this context may be targeted for degradation. Although not all PKC isotypes may trigger up-regulation of vesicle trafficking, any isotype capable of binding TPA and becoming membrane associated could be drawn into a degradative pathway passively. This would be consistent with one explanation afforded for the observed down-regulation of a kinase-inactive mutant of PCK-a in the context of a cell expressing endogenous (active) wild-type PCK-a 1231.
It should be noted that the present data indicate that there is no role for m-calpain in the increased proteolysis associated with down-regulation. However, it remains possible that biological responses to TPA can be mediated by a calpaindependent generation of PKM. Indeed, triggering the increased rate of PCK-a mutant degradation described in this study could yet be dependent upon calpain-dependent proteolysis of the endogenous COS cell PKC-a. Such a situation might explain the finding that PKC down-regulation can be inhibited by a calpain inhibitor [24] . Thus, it can only be concluded that the up-regulated pathway of proteolysis does not involve calpain and that the means of up-regulation remain obscure.
In conclusion, the data presented show that m-calpain does not appear to be responsible for phorbol-ester-induced down-regulation of PCK-a. The data suggest that the specificity of the process involved is broader than previously thought and, by inference, may involve sorting to a general degradative pathway possibly involving the lysosomal compartment.
